DE69007975D1 - Fusionsprotein bestehend aus gm-csf und il-3. - Google Patents

Fusionsprotein bestehend aus gm-csf und il-3.

Info

Publication number
DE69007975D1
DE69007975D1 DE90914297T DE69007975T DE69007975D1 DE 69007975 D1 DE69007975 D1 DE 69007975D1 DE 90914297 T DE90914297 T DE 90914297T DE 69007975 T DE69007975 T DE 69007975T DE 69007975 D1 DE69007975 D1 DE 69007975D1
Authority
DE
Germany
Prior art keywords
csf
fusion protein
protein consisting
alone
combined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE90914297T
Other languages
English (en)
Other versions
DE69007975T2 (de
Inventor
Benson Curtis
Linda Park
David Cosman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DE69007975D1 publication Critical patent/DE69007975D1/de
Application granted granted Critical
Publication of DE69007975T2 publication Critical patent/DE69007975T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69007975T 1989-08-22 1990-08-14 Fusionsprotein bestehend aus gm-csf und il-3. Expired - Fee Related DE69007975T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39714689A 1989-08-22 1989-08-22
PCT/US1990/004599 WO1991002754A1 (en) 1989-08-22 1990-08-14 Fusion proteins comprising gm-csf and il-3

Publications (2)

Publication Number Publication Date
DE69007975D1 true DE69007975D1 (de) 1994-05-11
DE69007975T2 DE69007975T2 (de) 1994-07-21

Family

ID=23570012

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69007975T Expired - Fee Related DE69007975T2 (de) 1989-08-22 1990-08-14 Fusionsprotein bestehend aus gm-csf und il-3.

Country Status (11)

Country Link
EP (1) EP0489116B1 (de)
JP (1) JP3115318B2 (de)
AT (1) ATE103932T1 (de)
AU (1) AU632372B2 (de)
DD (1) DD297188A5 (de)
DE (1) DE69007975T2 (de)
DK (1) DK0489116T3 (de)
ES (1) ES2055445T3 (de)
FI (1) FI920764A0 (de)
NO (1) NO301888B1 (de)
WO (1) WO1991002754A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651152B2 (en) * 1990-08-29 1994-07-14 Genetics Institute, Llc Multidomain hematopoiesis stimulators
CA2069746A1 (en) * 1990-09-28 1992-03-29 Jonathan I. Rosen Hybrid growth factors
ATE241011T1 (de) * 1991-02-27 2003-06-15 Micromet Ag Serin-reiche peptidlinker
DE69231467T2 (de) 1991-05-10 2001-01-25 Genentech Inc Auswählen von agonisten und antagonisten von liganden
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
CA2116533A1 (en) * 1991-08-30 1993-03-18 George J. Todaro Hybrid cytokines
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US7091319B1 (en) 1992-11-24 2006-08-15 Bauer S Christopher IL-3 variant hematopoiesis fusion protein
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US6361977B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
WO1994012639A2 (en) 1992-11-24 1994-06-09 G. D. Searle & Co. Interleukin-3 (il-3) mutant polypeptides
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
WO1996001903A1 (en) * 1994-07-07 1996-01-25 Immunex Corporation Fusion proteins comprising gm-csf and antigens and their expression in yeast
US6017523A (en) * 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
KR20130032866A (ko) * 2010-02-18 2013-04-02 더 유니버시티 오브 멜버른 만성 염증 상태의 치료
CA2861927C (en) 2012-01-20 2021-01-26 Vib Vzw Targeted mutant alpha-helical bundle cytokines
SG10201808738WA (en) * 2013-07-18 2018-11-29 Vib Vzw Fusokines involving cytokines with strongly reduced receptor binding affinities
BR112016001114B1 (pt) 2013-07-19 2023-02-14 Vib Vzw Composição compreendendo uma proteína de fusão e uso da referida composição
SG11201600167SA (en) 2013-07-19 2016-02-26 Vib Vzw Targeted modified il-1 family members
SG11201600165WA (en) 2013-07-19 2016-02-26 Vib Vzw Targeting of cytokine antagonists
JP6067540B2 (ja) * 2013-11-07 2017-01-25 日本曹達株式会社 防蟻性能試験用器具
EP3371311B1 (de) 2015-11-06 2021-07-21 Orionis Biosciences BV Bifunktionale chimäre proteine und verwendungen davon
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
WO2017134305A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Bispecific signaling agents and uses thereof
EP3426278B1 (de) 2016-03-07 2024-01-03 Vib Vzw Einzeldomänenantikörper gegen cd20
JP7105200B2 (ja) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
CA3023881A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
JP2020505955A (ja) 2017-02-06 2020-02-27 オリオンズ バイオサイエンス インコーポレイテッド 標的化改変型インターフェロン及びその使用
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
JP7347899B2 (ja) 2017-08-09 2023-09-20 オリオンズ バイオサイエンス インコーポレイテッド Ｃｄ８結合物質
US11440943B2 (en) 2019-03-28 2022-09-13 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0167548B1 (de) * 1983-12-23 1993-02-10 The Australian National University Klonierung von cdna und expression von mäuse-interleukin
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
DE3712985A1 (de) * 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
EP0276846A3 (de) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Derivate des koloniestimulierenden Faktors
OA09736A (en) * 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".

Also Published As

Publication number Publication date
FI920764A0 (fi) 1992-02-21
JP3115318B2 (ja) 2000-12-04
JPH05500806A (ja) 1993-02-18
EP0489116A1 (de) 1992-06-10
DD297188A5 (de) 1992-01-02
ES2055445T3 (es) 1994-08-16
NO920703L (no) 1992-04-14
DK0489116T3 (da) 1994-05-02
AU632372B2 (en) 1992-12-24
AU6424090A (en) 1991-04-03
DE69007975T2 (de) 1994-07-21
ATE103932T1 (de) 1994-04-15
NO301888B1 (no) 1997-12-22
EP0489116B1 (de) 1994-04-06
WO1991002754A1 (en) 1991-03-07
NO920703D0 (no) 1992-02-21

Similar Documents

Publication Publication Date Title
DE69007975D1 (de) Fusionsprotein bestehend aus gm-csf und il-3.
ATE339507T1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
MX9203426A (es) Proteinas de fusion que comprenden gm-csf e il-3.
DE69931507D1 (de) Interferon-beta fusionsproteine und deren verwendungen
ES2031806T3 (es) Factor de permeabilidad vascular humano.
DE69434520D1 (de) Biotinylierung von proteinen
FI972657A0 (fi) Proteiinien ja peptidien aerosoliformuloinnit
BR9407583A (pt) Processos para produzir uma proteina bcl-2 mutante para identificar agentes modulantes de bcl-2 candidatos um bcl-2 mutante e proteinas bcl-2 mutantes e para inibir a atividade repressora de morte de células de bcl-2 e polipeptideo bcl-2 mutante
GB9119043D0 (en) Fusion proteins containing n-terminal fragments of human serum albumin
FI954657A (fi) Biologisesti aktiivisia polypeptidifuusiodimeereja
DE69520475D1 (de) Pharmaceutische Zusammensetzung von biologisch aktiven Peptiden oder Proteinen
KR950702242A (ko) 사포린 함유 단백질의 재조합 생산방법(Recombinant production of saporin-containing proteins)
DK403384A (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
DE69123345D1 (de) Sequenzielle c-termin degradierung von peptiden und proteinen
DE68925304D1 (de) Minimale Derivatisierung von Proteinen
FI953422A0 (fi) Autolysoivia fuusioproteiineja hyväksikäyttävät ilmentämisjärjestelmät ja uusi pelkistävä polypeptidi
EP0669933A4 (de) Reinigung von fusionsproteinen, die gm-csf und il-3 enthalten.
NO881502L (no) Rekombinante htlv-111-proteiner og anvendelser av disse.
NO924165D0 (no) Proteasedefisiente bakterieverter
NO891926D0 (no) Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater.
MY114223A (en) Fusion proteins comprising gm-csf and il-3
IL96688A0 (en) Expression of delta-endotoxin proteins
DE69033553T2 (de) Rekombinante herstellung von laktoperoxidase
DE59008693D1 (de) Gewebs-Plasminogen-Aktivator-Derivat.
ITRM920517A0 (it) Procedimento di produzione della proteina sv-iv ricombinante e proteina sv-iv ricombinante.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee